NAD+: What the Research Actually Shows
A coenzyme central to mitochondrial energy production, sirtuin activity, and DNA repair that reliably declines with age in human tissue, with real randomized trial data for oral precursor forms (NMN, NR) showing modest, specific benefits, and a real, recent finding that the IV-infusion form most commonly marketed in longevity clinics has a notably worse tolerability profile than the oral alternative it was compared against.
A Coenzyme Central to Cellular Energy Metabolism, Not a Peptide or Hormone
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, required for the mitochondrial reactions that convert food into usable cellular energy (ATP), for sirtuin enzymes (SIRT1 and related proteins) that regulate mitochondrial biogenesis and metabolic gene expression, and for PARP enzymes that repair damaged DNA. NAD+ is not administered as NAD+ itself in most oral protocols, because dietary NAD+ is poorly absorbed intact; instead, most human research and most commercial products use NAD+ precursor molecules, nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR), that the body converts into NAD+ through a well-characterized salvage pathway. Direct NAD+ is also administered by IV infusion in many longevity and wellness clinics, a distinct delivery route with its own, much smaller, body of direct human evidence, addressed separately below. Neither NAD+ itself nor its precursors are FDA-approved therapeutic drugs; NMN and NR are sold as dietary supplements.
Evidence Summary
A Well-Established Mechanism, Modest Precursor-Pill Evidence, and a Concerning IV-Specific Finding
NAD+ Declines With Age in Human Tissue, Directly Measured
Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. "Age-Associated Changes in Oxidative Stress and NAD+ Metabolism in Human Tissue." PLOS ONE. 2012;7(7):e42357. doi: 10.1371/journal.pone.0042357. This study measured NAD+ levels directly in human skin tissue from 49 participants ranging from newborns to age 77, and found a strong, statistically significant inverse correlation between tissue NAD+ and age in both sexes (r=-0.706 in post-pubescent males, r=-0.537 in post-pubescent females). PARP enzyme activity rose with age and inversely tracked with falling NAD+ levels, consistent with age-related DNA-repair demand consuming the NAD+ supply. This is direct human tissue measurement, not an animal-model extrapolation.
Human Tissue Study (n=49, Ages Newborn to 77) · Endpoint: Direct Tissue NAD+ and PARP Activity Measurement Across the Lifespan, ObservationalMechanism: The NAD+/PARP1/SIRT1 Axis
Mendelsohn AR, Larrick JW. "The NAD+/PARP1/SIRT1 Axis in Aging." Rejuvenation Research. 2017;20(3):244-247. doi: 10.1089/rej.2017.1980. PMID: 28537485. This review lays out the mechanistic backbone connecting NAD+ decline to functional aging changes: falling NAD+ reduces SIRT1 activity and allows the protein DBC1 to bind and inhibit PARP1, impairing the cell's capacity for DNA repair via nonhomologous end joining and homologous recombination. Restoring NAD+ levels, at least in preclinical models, can disrupt this inhibitory complex and restore more youthful PARP1 activity and mitochondrial and stem cell function.
Mechanistic Review · Endpoint: NAD+/Sirtuin/PARP Signaling Pathway, Mechanistic Synthesis, Not New Primary DataOral NMN: A Real but Narrow Human Benefit
Yoshino M, Yoshino J, Kayser BD, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224-1229. This randomized, placebo-controlled trial gave oral NMN to 25 postmenopausal women with overweight or obesity and prediabetes over 10 weeks. Muscle insulin sensitivity improved significantly with NMN versus placebo, but the trial explicitly found no significant difference in liver insulin sensitivity or overall fasting glucose between groups. This is a real, randomized, human clinical finding, specific to a narrow outcome (muscle insulin signaling) in a specific population, not a broad metabolic or anti-aging effect.
Human RCT (n=25), Randomized, Placebo-Controlled · Endpoint: Muscle-Specific Insulin Sensitivity at 10 Weeks, Positive Finding, Explicitly Negative on Liver Insulin Sensitivity and Fasting GlucoseOral Nicotinamide Riboside: Raises NAD+ Reliably, Without Broad Functional Benefit in Healthy Adults
Martens CR, Denman BA, Mazzo MR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications. 2018;9:1286. doi: 10.1038/s41467-018-03421-7. This randomized, placebo-controlled, crossover trial gave 1,000 mg daily oral NR to healthy middle-aged and older adults (24 completers) for six weeks. NAD+ in blood cells rose approximately 60% versus placebo, and the supplement was well-tolerated with no serious adverse events. However, the trial found no significant improvements in metabolic function, exercise capacity, or motor performance in this healthy cohort, a real biomarker change without a demonstrated functional benefit in people who were not metabolically impaired to begin with.
Human RCT (n=24), Randomized, Placebo-Controlled, Crossover Design · Endpoint: Blood NAD+ Level at 6 Weeks, Positive on Biomarker, Explicitly Negative on Functional Outcomes in Healthy AdultsA Direct Comparison Worth Knowing: IV NAD+ vs. IV Nicotinamide Riboside
Reyna K, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging. 2026;7:1652582. doi: 10.3389/fragi.2026.1652582. PMID: 41704678. This retrospective, real-world pilot study compared clients who received IV NAD+ (n=6) against clients who received IV nicotinamide riboside (n=8) at the same clinic. Every client in the IV NAD+ group reported moderate-to-severe adverse effects during infusion, including abdominal cramping, diarrhea, nausea, vomiting, elevated heart rate, throat pain, congestion, and chest pressure; the NR group reported only minor tingling and cramping. IV NAD+ also took nearly three times longer to infuse (97 minutes versus 37 minutes) and was associated with a decrease in HDL cholesterol, while the NR group showed a significant improvement in HbA1c and no such lipid change. This is a small, retrospective pilot comparison, not a large randomized trial, but it is a real, recent, direct, real-world comparison of exactly the two delivery approaches most commonly marketed side by side in longevity clinics, and its finding runs directly counter to any assumption that direct IV NAD+ is the more effective or better-tolerated option.
Retrospective Real-World Pilot Study (n=14 Total) · Endpoint: Tolerability, Adverse Effects, and Metabolic Biomarkers, Direct Comparison of Two Marketed Delivery Methods, Small and RetrospectiveWhat the Research Doesn't Yet Show
The gap between NAD+'s well-established cellular mechanism and the actual clinical trial evidence is real and worth stating directly. No large randomized trial has demonstrated that raising NAD+ levels, by any delivery method, extends human lifespan or reverses aging broadly; the human data that exists shows specific, modest effects (muscle insulin sensitivity in one prediabetic population, a reliable rise in blood NAD+ in healthy older adults) rather than the sweeping anti-aging claims common in marketing for NAD+ products. Direct IV NAD+ infusion in particular, the form most heavily marketed and most expensive in longevity clinic settings, has the least direct human trial evidence of the approaches covered here, and the one real-world comparative study available found it tolerated meaningfully worse than an oral-precursor IV alternative, with no compensating metabolic advantage. Neither NAD+ nor its precursors are FDA-approved therapeutic drugs; NMN and NR are sold and regulated as dietary supplements, a different regulatory category than a prescription medication, and that status should inform expectations about the strength of evidence and oversight behind any specific product.
How This Fits the Cellular Medicine Framework
NAD+ sits closer to the metabolic and mitochondrial-function tiers of this framework than the cell-signaling tier most peptides and hormones on this site occupy: it isn't a messenger activating a receptor, it's a required cofactor the mitochondria and DNA-repair machinery cannot function without, more analogous to a fuel or a tool than a signal. That distinction matters for how to read the evidence here: a hormone or peptide's evidence question is usually "does this signal produce the intended downstream effect," while NAD+'s evidence question is closer to "does topping up a required cofactor, when the surrounding machinery is otherwise intact, meaningfully change function," and the honest answer from the trials above is: sometimes, specifically, and not automatically. NAD+ is a genuine example of why this framework insists on tracing all the way from mechanism to clinical phenotype rather than stopping at a well-understood biochemical role.
NAD+ and NADH are themselves one of the central redox couples of cellular metabolism, which is why NAD+ status is also a redox biology question, not just a mitochondrial fuel-supply one.
References
- Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-Associated Changes in Oxidative Stress and NAD+ Metabolism in Human Tissue. PLOS ONE. 2012;7(7):e42357. doi:10.1371/journal.pone.0042357
- Mendelsohn AR, Larrick JW. The NAD+/PARP1/SIRT1 Axis in Aging. Rejuvenation Res. 2017;20(3):244-247. doi:10.1089/rej.2017.1980 · PMID: 28537485
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. doi:10.1038/s41467-018-03421-7
- Reyna K, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. doi:10.3389/fragi.2026.1652582 · PMID: 41704678
Explore the Rest of the Knowledge Center
Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.